Roger S McIntyre

Roger S McIntyre, MD, FRCPC

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also director for the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA.
 
Dr. McIntyre was named by Clarivate Analytics/Thomson Reuters in 2014, 2015, 2016, and 2017 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. 
 
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity.  His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. 
 
Dr. McIntyre is extensively involved in medical education.  He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
 
Dr. McIntyre is a contributor to the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre was the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. Dr. McIntyre has published more than 400 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders. 
 
Dr. McIntyre completed his medical degree at Dalhousie University.  He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity.  Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Pharmacopsychiatry. 2018 Apr 16;:
Tsai CJ, Chiu WC, Chen CJ, Chen PC, McIntyre RS, Chen VC
Expert Opin Drug Metab Toxicol. 2018 Apr 06;:1-8
Ragguett RM, Rong C, Rosenblat JD, Ho RC, McIntyre RS
Can J Diabetes. 2017 Dec 18;:
Tarride JE, Smofsky A, Nykoliation P, Allain S, Lewis-Daly L, Satok D, Schwartz J, Pollack JH, Guertin JR, McIntyre RS
Bipolar Disord. 2018 Mar 14;:
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B,...
J Clin Psychiatry. 2018 Jan/Feb;79(1):
McIntyre RS
J Am Soc Hypertens. 2018 Feb 16;:
Park SK, Jung JY, Ryoo JH, Oh CM, Lee JH, Pan Z, Mansur RB, Shekotikhina M, McIntyre RS, Choi JM
Neuropharmacology. 2018 Feb 23;:
Mansur RB, Lee Y, Subramaniapillai M, Brietzke E, McIntyre RS
Psychoneuroendocrinology. 2018 Feb 03;90:61-67
Queissner R, Pilz R, Dalkner N, Birner A, Bengesser SA, Platzer M, Fellendorf FT, Kainzbauer N, Herzog-Eberhard S, Hamm C, Reininghaus B, Zelzer S, Mangge H, Mansur RB, McIntyre RS, Kapfhammer HP, Reininghaus EZ
Perspect Psychiatr Care. 2018 Feb 10;:
Aladeen T, Westphal E, Lee Y, Rong C, Rainka M, Capote H, McIntyre RS

Pages


 

Head, Mood Disorders Psychopharmacology Unit, UHN
Professor, Departments of Psychiatry and Pharmacology and Toxicology, University of Toronto